UROLOGIC NEOPLASMS
Clinical trials for UROLOGIC NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new UROLOGIC NEOPLASMS trials appear
Sign up with your email to follow new studies for UROLOGIC NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat HER2 cancers
Disease control OngoingThis study tests a combination of two drugs, tucatinib and trastuzumab, in people with advanced solid tumors that have HER2 alterations (too much or a different type of HER2 protein). The tumors have spread or cannot be removed by surgery. The main goal is to see if the treatment…
Matched conditions: UROLOGIC NEOPLASMS
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New hope for rare kidney cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis study tests a new drug called savolitinib against a standard treatment (sunitinib) for people with a rare, advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib works better at slowing cancer growth and has fewer side effe…
Matched conditions: UROLOGIC NEOPLASMS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 15, 2026 11:53 UTC